Sanj K. Patel Sells 4,837 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) CEO Sanj K. Patel sold 4,837 shares of the firm's stock in a transaction that occurred on Friday, May 23rd. The stock was sold at an average price of $27.00, for a total transaction of $130,599.00. Following the transaction, the chief executive officer now directly owns 96,674 shares in the company, valued at approximately $2,610,198. This trade represents a 4.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Kiniksa Pharmaceuticals Trading Up 0.9%

Shares of Kiniksa Pharmaceuticals stock traded up $0.25 during trading hours on Friday, reaching $27.43. The stock had a trading volume of 543,644 shares, compared to its average volume of 492,782. The stock's 50 day moving average is $23.62 and its 200 day moving average is $21.64. The firm has a market capitalization of $2.00 billion, a PE ratio of -195.91 and a beta of 0.07. Kiniksa Pharmaceuticals, Ltd. has a twelve month low of $17.38 and a twelve month high of $28.56.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, topping analysts' consensus estimates of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business had revenue of $137.79 million during the quarter, compared to the consensus estimate of $128.35 million. During the same quarter in the prior year, the firm posted ($0.25) earnings per share. The company's revenue was up 72.5% compared to the same quarter last year. As a group, sell-side analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

Institutional Trading of Kiniksa Pharmaceuticals

Several large investors have recently bought and sold shares of KNSA. Corebridge Financial Inc. grew its stake in shares of Kiniksa Pharmaceuticals by 3.6% in the 1st quarter. Corebridge Financial Inc. now owns 15,979 shares of the company's stock valued at $355,000 after buying an additional 549 shares during the period. GAMMA Investing LLC grew its stake in shares of Kiniksa Pharmaceuticals by 84.8% in the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock valued at $27,000 after buying an additional 568 shares during the period. Sound View Wealth Advisors Group LLC grew its stake in shares of Kiniksa Pharmaceuticals by 4.0% in the 1st quarter. Sound View Wealth Advisors Group LLC now owns 14,657 shares of the company's stock valued at $326,000 after buying an additional 568 shares during the period. Martingale Asset Management L P grew its stake in shares of Kiniksa Pharmaceuticals by 1.3% in the 1st quarter. Martingale Asset Management L P now owns 50,000 shares of the company's stock valued at $1,111,000 after buying an additional 640 shares during the period. Finally, Teacher Retirement System of Texas boosted its position in shares of Kiniksa Pharmaceuticals by 7.1% during the 4th quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company's stock worth $215,000 after purchasing an additional 719 shares during the period. Hedge funds and other institutional investors own 53.95% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on KNSA shares. Citigroup started coverage on shares of Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They set a "buy" rating and a $40.00 price objective on the stock. Wedbush reissued an "outperform" rating and set a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a report on Wednesday, April 16th. Finally, Jefferies Financial Group lifted their price objective on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the company a "buy" rating in a report on Tuesday, April 29th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $38.80.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.